Autopsy report · NCT00490100

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

“Insufficient patient participation”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 6 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 2 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Sponsor type

US National Institutes of Health

Conditions

Growth Failure; X-linked Severe Combined Immunodeficiency (XSCID); Growth Hormone Resistence

Interventions

Increlex

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques
  “Lack of eligible patients willing and able to participate” (82% match in meaning)
• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (79% match in meaning)
• Daptomycin in Pediatric Patients With Bacterial Meningitis
  “Insufficient patient recruitment” (78% match in meaning)
• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
  “Lack of patient accruals.” (77% match in meaning)
• Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery
  “Inadequate patient enrollment” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.